Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment

Identification of novel vulnerabilities in the context of therapeutic resistance is emerging as a key challenge for cancer treatment. Recent studies have detected pervasive aberrant splicing in cancer cells, supporting its targeting for novel therapeutic strategies. Here, we evaluated the expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Soncini, Debora, Martinuzzi, Claudia, Becherini, Pamela, Gelli, Elisa, Ruberti, Samantha, Todoerti, Katia, Mastracci, Luca, Contini, Paola, Cagnetta, Antonia, Laudisi, Antonella, Guolo, Fabio, Minetto, Paola, Miglino, Maurizio, Aquino, Sara, Varaldo, Riccardo, Reverberi, Daniele, Formica, Matteo, Passalacqua, Mario, Nencioni, Alessio, Neri, Antonino, Samur, Mehmet K., Munshi, Nikhil C., Fulciniti, Mariateresa, Lemoli, Roberto M., Cea., Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152954/
https://www.ncbi.nlm.nih.gov/pubmed/34670358
http://dx.doi.org/10.3324/haematol.2021.279276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152954/
https://www.ncbi.nlm.nih.gov/pubmed/34670358
http://dx.doi.org/10.3324/haematol.2021.279276

Ejemplares similares